Press Releases

Press Releases

    Date Title View
    11/12/20
    Summary ToggleHorizon Therapeutics plc to Participate in Upcoming Investor Conferences
    PDF Version
    11/02/20
    Summary ToggleHigher Response Rates in RECIPE Randomized Controlled Trial of KRYSTEXXA® (pegloticase injection) Concomitantly Used with the Immunomodulator Mycophenolate Mofetil
    PDF Version
    11/02/20
    Summary ToggleHorizon Therapeutics plc Reports Record Third-Quarter 2020 Results; Increases TEPEZZA® Full-Year Net Sales Guidance to Greater Than $800 Million; Increases Full-Year 2020 Net Sales and Adjusted EBITDA Guidance
    11/02/20
    Summary ToggleHorizon Therapeutics plc Names Karin Rosén, M.D., Ph.D. Executive Vice President, Research and Development and Chief Scientific Officer
    PDF Version
    10/30/20
    Summary ToggleChicago Tribune Names Horizon Therapeutics a 2020 Top Workplace for the Sixth Consecutive Year
    PDF Version
    10/30/20
    Summary ToggleNew TEPEZZA® (teprotumumab-trbw) Data to Be Presented at the American Academy of Ophthalmology 2020 Annual Meeting
    PDF Version
    10/29/20
    Summary ToggleHorizon Therapeutics plc Initiates Clinical Trial to Assess Shorter Infusion Duration for KRYSTEXXA® (pegloticase injection) Concomitantly Used with Methotrexate to Treat Uncontrolled Gout
    PDF Version
    10/26/20
    Summary ToggleHorizon Therapeutics plc Named One of the Most Innovative Companies by Crain’s Chicago Business
    PDF Version
    10/23/20
    Summary ToggleHorizon Therapeutics plc Named One of the Best Adoption-Friendly Workplaces by the Dave Thomas Foundation for Adoption
    PDF Version
    10/22/20
    Summary ToggleNew Data Offers Insights on Treatment with KRYSTEXXA® (pegloticase injection) Among Kidney Transplant Patients for the Management of Uncontrolled Gout
    PDF Version
    Displaying 31 - 40 of 569 results